|
|
Volumn 24, Issue 2, 2016, Pages 193-194
|
|
New momentum for the field of oligonucleotide therapeutics
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTITHROMBIN III;
ASIALOGLYCOPROTEIN RECEPTOR;
DOUBLE STRANDED RNA;
DRISAPERSEN;
ETEPLIRSEN;
FOMIVIRSEN;
MICRORNA;
MIPOMERSEN;
N ACETYLGALACTOSAMINE;
OLIGONUCLEOTIDE;
PEGAPTANIB;
SINGLE STRANDED RNA;
SMALL INTERFERING RNA;
COMPLEMENTARY DNA;
ANTISENSE OLIGONUCLEOTIDE;
HEMOGLOBIN BETA CHAIN;
PHOSPHOROTHIOIC ACID;
RIBONUCLEASE H;
AMYOTROPHIC LATERAL SCLEROSIS;
CLINICAL TRIAL (TOPIC);
DRUG APPROVAL;
DRUG RESEARCH;
DRUG TARGETING;
DUCHENNE MUSCULAR DYSTROPHY;
EDITORIAL;
EXON;
FOOD AND DRUG ADMINISTRATION;
GENE EXPRESSION;
GENE SILENCING;
GENE TARGETING;
HUMAN;
HUNTINGTON CHOREA;
IN VITRO STUDY;
MALIGNANT NEOPLASTIC DISEASE;
NEUROLOGIC DISEASE;
OLIGONUCLEOTIDE THERAPY;
RNA TRANSCRIPTION;
SPINAL MUSCULAR ATROPHY;
ANTISENSE THERAPY;
BASE PAIRING;
CHEMICAL MODIFICATION;
GENE KNOCKDOWN;
HEMOPHILIA;
NONHUMAN;
RNA SPLICING;
CLINICAL TRIALS AS TOPIC;
DNA, ANTISENSE;
HUMANS;
OLIGONUCLEOTIDES;
|
|
EID: 84959466731
PISSN: 15250016
EISSN: 15250024
Source Type: Journal
DOI: 10.1038/mt.2016.14 Document Type: Editorial |
|
Times cited : (31)
|
|
References (0)
|
